Antigenicity and immunogenicity of sulphamethoxazole:: demonstration of metabolism-dependent haptenation and T-cell proliferation in vivo

被引:112
作者
Naisbitt, DJ
Gordon, SF
Pirmohamed, M
Burkhart, C
Cribb, AE
Pichler, WJ
Park, BK
机构
[1] Univ Liverpool, Dept Pharmacol & Therapeut, Liverpool L69 3BX, Merseyside, England
[2] Univ Bern, Inselspital, Klin Rheumatol & Klin Immunol Allergol, CH-3010 Bern, Switzerland
[3] Univ Prince Edward Isl, Lab Pharmacogenet, Charlottetown, PE C1A 4P3, Canada
关键词
delayed type hypersensitivity; skin; T-lymphocytes; antigen presentation; in vivo animal model; sulphamethoxatole;
D O I
10.1038/sj.bjp.0704074
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
1 Sulphamethoxazole has been associated with the occurrence of hypersensitivity reactions. There is controversy as to whether the immune response is metabolism-dependent or -independent. We have therefore investigated the site of antigen formation and the nature of the drug signal presented to the immune system in vivo. 2 Male Wistar rats were dosed with sulphamethoxazole, sulphamethoxazole hydroxylamine or nitroso sulphamethoxazole. Antigen formation on cell surfaces was determined by flow cytometry using a specific anti-sulphamethoxazole antibody. Immunogenicity was determined by assessment of ex vivo T-cell proliferation. 3 Administration of nitroso sulphamethoxazole, but not sulphamethoxazole or sulphamethoxazole hydroxylamine, resulted in antigen formation on the surface of lymphocytes, splenocytes and epidermal keratinocytes, and a strong proliferative response of splenocytes on re-stimulation with nitroso sulphamethoxazole. Rats dosed with sulphamethoxazole or sulphamethoxazole hydroxylamine did not respond to any of the test compounds. 4 CD4(+) or CD8(+) depleted cells responded equally to nitroso sulphamethoxazole. The proliferative response to nitroso sulphamethoxazole was seen even after pulsing for only 5 min, and was not inhibited by glutathione. Responding cells produced IFN-gamma, but not IL-4. 5 Haptenation of cells by sulphamethoxazole hydroxylamine was seen after depletion of glutathione by pre-treating the rats with diethyl maleate. Splenocytes from the glutathione-depleted sulphamethoxazole hydroxylamine-treated rats responded weakly to nitroso sulphamethoxazole, but not to sulphamethoxazole or sulphamethoxazole hydroxylamine. 6 Dosing of rats with sulphamethoxazole produced a cellular response to nitroso sulphamethoxatole (but not to sulphamethoxazole or its hydroxylamine) when the animals were primed with complete Freund's adjuvant. 7 These studies demonstrate the antigenicity of nitroso sulphamethoxazole in vivo and provide evidence for the role of drug metabolism and cell surface haptenation in the induction of a cellular immune response in the rat.
引用
收藏
页码:295 / 305
页数:11
相关论文
共 58 条
[1]  
Barranco P., 1998, Clinical and Experimental Allergy, V28, P61
[2]   Toxic epidermal necrolysis [J].
Becker, DS .
LANCET, 1998, 351 (9113) :1417-1420
[3]   ENZYME-CATALYSED CONJUGATIONS OF GLUTATHIONE WITH UNSATURATED COMPOUNDS [J].
BOYLAND, E ;
CHASSEAUD, LF .
BIOCHEMICAL JOURNAL, 1967, 104 (01) :95-+
[4]   Influence of reduced glutathione on the proliferative response of sulfamethoxazole-specific and sulfamethoxazole-metabolite-specific human CD4+T-cells [J].
Burkhart, C ;
Von Greyerz, S ;
Depta, JPH ;
Naisbitt, DJ ;
Britschgi, M ;
Park, KB ;
Pichler, WJ .
BRITISH JOURNAL OF PHARMACOLOGY, 2001, 132 (03) :623-630
[5]   THE TOXICOLOGICAL SIGNIFICANCE OF XENOBIOTIC METABOLISM [J].
CALDWELL, J ;
HOWES, AJ ;
HOTCHKISS, SA .
FOOD ADDITIVES AND CONTAMINANTS, 1990, 7 :S116-S126
[6]   Mechanisms of drug allergy [J].
Coleman, JW ;
Blanca, M .
IMMUNOLOGY TODAY, 1998, 19 (05) :196-198
[7]   CUTANEOUS DISEASE AND DRUG-REACTIONS IN HIV-INFECTION [J].
COOPMAN, SA ;
JOHNSON, RA ;
PLATT, R ;
STERN, RS .
NEW ENGLAND JOURNAL OF MEDICINE, 1993, 328 (23) :1670-1674
[8]   CUTANEOUS T-CELL RECRUITMENT IN TOXIC EPIDERMAL NECROLYSIS - FURTHER EVIDENCE OF CD8+ LYMPHOCYTE INVOLVEMENT [J].
CORREIA, O ;
DELGADO, L ;
RAMOS, JP ;
RESENDE, C ;
FLEMING, JA .
ARCHIVES OF DERMATOLOGY, 1993, 129 (04) :466-468
[9]  
CRIBB AE, 1991, DRUG METAB DISPOS, V19, P900
[10]  
CRIBB AE, 1995, DRUG METAB DISPOS, V23, P406